MARKET

INFIQ

INFIQ

Infinity Pharmaceuticals Inc
EXMKT
0.0002
NaN%
Closed 09:30 02/22 EST
OPEN
--
PREV CLOSE
0.0002
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.300
52 WEEK LOW
0.0001
MARKET CAP
18.15K
P/E (TTM)
-0.0004
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at INFIQ last week (0212-0216)?
Weekly Report · 4d ago
Weekly Report: what happened at INFIQ last week (0205-0209)?
Weekly Report · 02/12 09:29
Weekly Report: what happened at INFIQ last week (0129-0202)?
Weekly Report · 02/05 09:32
Weekly Report: what happened at INFIQ last week (0122-0126)?
Weekly Report · 01/29 09:30
Weekly Report: what happened at INFIQ last week (0115-0119)?
Weekly Report · 01/22 09:30
Weekly Report: what happened at INFIQ last week (0108-0112)?
Weekly Report · 01/15 09:30
Weekly Report: what happened at INFIQ last week (0101-0105)?
Weekly Report · 01/08 09:31
Weekly Report: what happened at INFIQ last week (1225-1229)?
Weekly Report · 01/01 09:29
More
About INFIQ
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Webull offers Infinity Pharmaceuticals Inc. stock information, including EXMKT: INFIQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INFIQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INFIQ stock methods without spending real money on the virtual paper trading platform.